Amalgamated Financial’s Pacific Biosciences PACB Stock Holding History

Amalgamated Financial’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$248K	Buy	+27,233	New	+$314K	﹤0.01%	1815

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Amalgamated Financial's PACB Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Pacific Biosciences (PACB) in Q1 2022: 27,233 shares worth $248K. The stake represents ﹤0.01% of the portfolio and ranks #1815 among its holdings.

250 funds tracked by Wall St. Rank hold PACB as of Q1 2022.

Amalgamated Financial held 27,233 shares of Pacific Biosciences worth $248K as of Q1 2022.
Pacific Biosciences was a new Amalgamated Financial position in Q1 2022.
Pacific Biosciences made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1815 holding.
250 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.